Global In Vitro Assays to Diagnose Infectious Diseases Market Growth (Status and Outlook) 2023-2029

Global In Vitro Assays to Diagnose Infectious Diseases Market Growth (Status and Outlook) 2023-2029

The global In Vitro Assays to Diagnose Infectious Diseases market size is projected to grow from US$ 3464.6 million in 2022 to US$ 3131.9 million in 2029; it is expected to grow at a CAGR of -1.4% from 2023 to 2029.

Enzyme-Linked Immunosorbent Assay (ELISA): ELISA is a highly sensitive and specific assay that detects the presence of antigens or antibodies in patient samples. ELISA can be used to diagnose a wide range of infectious diseases, including HIV, hepatitis, and Lyme disease.

In Vitro Assays to Diagnose Infectious Diseases market refers to the use of diagnostic tests and devices to detect and diagnose infectious diseases in biological samples such as blood, urine, and other bodily fluids. These tests are performed in vitro, meaning outside of the body in a laboratory setting. The IVD market for infectious diseases includes a range of tests such as immunoassays, molecular diagnostics, and microbiology culture tests, among others. These tests aid in the identification of infectious agents such as bacteria, viruses, fungi, and parasites, and help in the management and treatment of infectious diseases.

LPI (LP Information)' newest research report, the “In Vitro Assays to Diagnose Infectious Diseases Industry Forecast” looks at past sales and reviews total world In Vitro Assays to Diagnose Infectious Diseases sales in 2022, providing a comprehensive analysis by region and market sector of projected In Vitro Assays to Diagnose Infectious Diseases sales for 2023 through 2029. With In Vitro Assays to Diagnose Infectious Diseases sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world In Vitro Assays to Diagnose Infectious Diseases industry.

This Insight Report provides a comprehensive analysis of the global In Vitro Assays to Diagnose Infectious Diseases landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on In Vitro Assays to Diagnose Infectious Diseases portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global In Vitro Assays to Diagnose Infectious Diseases market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for In Vitro Assays to Diagnose Infectious Diseases and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global In Vitro Assays to Diagnose Infectious Diseases.

This report presents a comprehensive overview, market shares, and growth opportunities of In Vitro Assays to Diagnose Infectious Diseases market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Immunoassay
Molecular Diagnosis
Others

Segmentation by application
Streptococcus
Clostridium Difficile
Candida
Tuberculosis
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
QIAGEN
BD
bioMerieux SA
F. Hoffmann-La Roche, Ltd.
Hologic, Inc. (Gen-Probe)
Abbott
Quidel Corp.、
iemens Healthineers AG
Bio-Rad Laboratories, Inc.
Danaher Corp.
OraSure Technologies, Inc

Please note: The report will take approximately 2 business days to prepare and deliver.